Beijing Kawin Technology Share-Holding Co., Ltd. engages in the development and production of pharmaceutical products primarily in the areas of liver diseases in China. The company's products include recombinant human interferon alfa-2b injection; vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; and compound glycyrrhizin. It has strategic partnership with Legend Capital, Haitong Capital, and Cybernaut. The company was founded in 2008 and is based in Beijing, China.